Item 8.01 Other Events.

As previously disclosed, on September 30, 2020, 180 Life Sciences Corp. (the "Company") received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company's common stock failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by Nasdaq Listing Rule 5550(a)(2).

On January 4, 2023, the Company received a letter from Nasdaq notifying the Company that it has regained full compliance with the minimum bid price for continued listing on Nasdaq, pursuant to Nasdaq Listing Rule 5550(a)(2)(the "Minimum Bid Price Requirement"), because Nasdaq has determined that for 10 consecutive business days, the closing bid price of the Company's common stock was at or above $1.00 per share.

Accordingly, the Company has regained compliance with the Minimum Bid Price Requirement and the matter is now closed.

On January 5, 2023, the Company filed a press release disclosing the fact that it has regained compliance with the Minimum Bid Price Requirement. A copy of the press release is included herewith as Exhibit 99.1 and the information in the press release is incorporated by reference into this Item 8.01.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits



Exhibit
Number    Exhibit Description
99.1        Press Release, dated January 5, 2023
104       Cover Page Interactive Data File (embedded within Inline XBRL document).




                                       1

© Edgar Online, source Glimpses